Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2014 (2014), Article ID 802307, 5 pages
http://dx.doi.org/10.1155/2014/802307
Clinical Study

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis

1MS Centre, Department of Neurology and Psychiatry, Sapienza University, Viale dell’Università, 30-00185 Rome, Italy
2Physical Therapy Unit, S. Andrea Hospital, via di Grottarossa, 1035-00189 Rome, Italy

Received 22 January 2014; Accepted 1 March 2014; Published 27 March 2014

Academic Editor: Francesco Patti

Copyright © 2014 Luca Prosperini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Gijbels, G. Alders, E. van Hoof et al., “Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures,” Multiple Sclerosis, vol. 16, no. 5, pp. 618–626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. P. van Asch, “Impact of mobility impairment in multiple sclerosis 2—patient perspectives,” European Neurological Review, vol. 6, pp. 115–120, 2011. View at Google Scholar
  3. A. J. Thompson, A. T. Toosy, and O. Ciccarelli, “Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions,” The Lancet Neurology, vol. 9, no. 12, pp. 1182–1199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Stolze, S. Klebe, C. Zechlin, C. Baecker, L. Friege, and G. Deuschl, “Falls in frequent neurological diseases: prevalence, risk factors and aetiology,” Journal of Neurology, vol. 251, no. 1, pp. 79–84, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Bostock, T. A. Sears, and R. M. Sherratt, “The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres,” Journal of Physiology, vol. 313, pp. 301–315, 1981. View at Google Scholar · View at Scopus
  6. A. D. Goodman, J. A. Cohen, A. Cross et al., “Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study,” Multiple Sclerosis, vol. 13, no. 3, pp. 357–368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. D. Goodman, T. R. Brown, J. A. Cohen et al., “Dose comparison trial of sustained-release fampridine in multiple sclerosis,” Neurology, vol. 71, no. 15, pp. 1134–1141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. D. Goodman, T. R. Brown, L. B. Krupp et al., “Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial,” The Lancet, vol. 373, no. 9665, pp. 732–738, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. D. Goodman, T. R. Brown, K. R. Edwards et al., “A phase 3 trial of extended release oral dalfampridine in multiple sclerosis,” Annals of Neurology, vol. 68, no. 4, pp. 494–502, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. http://clinicaltrials.gov/ct2/show/NCT01597297?term=mobile+and+dalfampridine&rank=1.
  11. C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of Neurology, vol. 69, pp. 292–302, 2011. View at Google Scholar
  12. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002097/human_med_001432.jsp&mid=WC0b01ac058001d124.
  13. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Google Scholar · View at Scopus
  14. G. R. Cutter, M. L. Baier, R. A. Rudick et al., “Development of a multiple sclerosis functional composite as a clinical trial outcome measure,” Brain, vol. 122, no. 5, pp. 871–882, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Cattaneo and J. Jonsdottir, “Sensory impairments in quiet standing in subjects with multiple sclerosis,” Multiple Sclerosis, vol. 15, no. 1, pp. 59–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Prosperini, D. Fortuna, C. Giannì et al., “The diagnostic accuracy of static posturography in predicting accidental falls in people with multiple sclerosis,” Neurorehabilitation and Neural Repair, vol. 27, pp. 45–52, 2013. View at Google Scholar
  17. G. P. Jacobson and C. W. Newman, “The development of the Dizziness Handicap Inventory,” Archives of Otolaryngology—Head and Neck Surgery, vol. 116, no. 4, pp. 424–427, 1990. View at Google Scholar · View at Scopus
  18. D. Cattaneo, A. Regola, and M. Meotti, “Validity of six balance disorders scales in persons with multiple sclerosis,” Disability and Rehabilitation, vol. 28, no. 12, pp. 789–795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Ruck, S. Bittner, O. J. Simon et al., “Long-term effects of dalfampridine in patients with multiple sclerosis,” Journal of the Neurological Sciences, vol. 337, no. 1, pp. 18–24, 2014. View at Publisher · View at Google Scholar
  20. C. Mainero, M. Inghilleri, P. Pantano et al., “Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine,” Neurology, vol. 62, no. 11, pp. 2044–2050, 2004. View at Google Scholar · View at Scopus
  21. R. T. Jackson, C. M. Epstein, and W. R. de l'Aune, “Abnormalities in posturography and estimations of visual vertical and horizontal in multiple sclerosis,” American Journal of Otology, vol. 16, no. 1, pp. 88–93, 1995. View at Google Scholar · View at Scopus
  22. V. Krishnan, N. Kanekar, and A. S. Aruin, “Anticipatory postural adjustments in individuals with multiple sclerosis,” Neuroscience Letters, vol. 506, no. 2, pp. 256–260, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Alviña and K. Khodakhah, “The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia,” Journal of Neuroscience, vol. 30, no. 21, pp. 7258–7268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Strupp, R. Kalla, S. Glasauer et al., “Aminopyridines for the treatment of cerebellar and ocular motor disorders,” Progress in Brain Research, vol. 171, pp. 535–541, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Schmidt, “Fampridine improves severe dysarthria in secondary-progressive multiple sclerosis.,” Multiple Sclerosis, vol. 19, article 511, 2013. View at Google Scholar
  26. R. Schniepp, V. Jakl, M. Wuehr et al., “Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report,” Multiple Sclerosis, vol. 19, no. 4, pp. 506–508, 2012. View at Publisher · View at Google Scholar
  27. L. Prosperini, E. Sbardella, E. Raz et al., “White and grey matter damage associated with balance deficit as detected by static posturography in multiple sclerosis,” Radiology, vol. 268, pp. 181–189, 2013. View at Google Scholar
  28. L. Prosperini and C. Pozzilli, “The clinical relevance of force platform measures in multiple sclerosis: a review,” Multiple Sclerosis International, vol. 2013, Article ID 756564, 9 pages, 2013. View at Publisher · View at Google Scholar